Researchers from the Chinese Academy of Sciences recently published a preprint of a study where they analyzed the genomic sequence of the OMICRON variant of COVID-19 and determined that it could not have evolved in the public in the same semi-natural, vaccine-accelerated manner that other variants like Delta did.

The researchers titled their paper: “Evidence for a mouse origin of the SARS-CoV-2 Omicron variant.” Yes, that’s right. The researchers found that the pattern of mutations in Omicron did not match mutations that would be expected in humans, but did match mutations that would be expected in mice. Here’s what they wrote:

The rapid accumulation of mutations in the SARS-CoV-2 Omicron variant that enabled its outbreak raises questions as to whether its proximal origin occurred in humans or another mammalian host. Here, we identified 45 point mutations that Omicron acquired since divergence from the B.1.1 lineage. We found that the Omicron spike protein sequence was subjected to stronger positive selection than that of any reported SARS-CoV-2 variants known to evolve persistently in human hosts, suggesting a possibility of host-jumping. The molecular spectrum of mutations (i.e., the relative frequency of the 12 types of base substitutions) acquired by the progenitor of Omicron was significantly different from the spectrum for viruses that evolved in human patients, but resembled the spectra associated with virus evolution in a mouse cellular environment. Furthermore, mutations in the Omicron spike protein significantly overlapped with SARS-CoV-2 mutations known to promote adaptation to mouse hosts, particularly through enhanced spike protein binding affinity for the mouse cell entry receptor. Collectively, our results suggest that the progenitor of Omicron jumped from humans to mice, rapidly accumulated mutations conducive to infecting that host, then jumped back into humans, indicating an inter-species evolutionary trajectory for the Omicron outbreak.

This type of host jumping is called Reverse Zoonosis, where it goes from humans to mice, and then even back to humans. William Haseltine writes: “The likelihood that this may have occurred is entirely plausible, and may indeed be probable. Since its emergence, this particular coronavirus has infected our entire biosphere, from minks and mice to deer and rats, not to mention our own selves. In each of these animal populations, just like in humans, the virus has evolved and adapted to immune pressure, so far surviving in each population to infect and reinfect.”

Haseltine wrote of another potential disturbing origin of Omicron though, Merck’s trials of their “drug” molnupiravir. Molnupiravir is designed to mutate SARS2. Haseltine: “Molnupiravir works by introducing errors into the virus’ genetic code. When enough errors are introduced, virus replication slows and the patient clears the virus.” 

“Under less than ideal conditions — when the full dose of molnupiravir is not taken over the full period of five days, for example — the drug could lead to the creation of highly mutated, but viable, strains of SARS-CoV-2.”

“In South Africa, where Omicron was first detected, molnupiravir has been taken in both ideal and non-ideal conditions. Four different South African locations were used in Merck’s clinical trial of molnupiravir, which began in October 2020.”

Yes, molnupiravir could be the gift that keeps on giving to pharma by creating any number of mutated viruses for them to once again profit from by selling us the “cures” of diseases they have caused, and their “cures” again contain disease, and so on…

The insanity of releasing molnupiravir into the public, even for testing, is beyond comprehension. Decisions like these defy logic to the extent that only criminal intent on the part of the FDA to kill the public can be surmised, especially when other actual safe, effective and cheap treatments are well-known to exist in the medical community all over the world.

The New York Times recently reported that molnupiravir can be expected to cause DNA damage, cancer, and birth defects. An FDA panel voted 13-10 to recommend an Emergency Use Authorization anyway.

The researchers from the Chinese Academy of Sciences did not discuss the possibility of Merck’s molnupiravir generating the type of mutations they discovered in Omicron. “Humanized mice models” were involved in the testing of molnupiravir at some point. I’ll leave the question “Merck or Mice” to further discussion of science.